HumansareCapableofGreatness
Capable compiles frontier intelligence into frontier medicines.
Backed early with $12M by
Our Team
Helena
Rose
Rose
Isaak
Freeman
Freeman
George
Church
Church
Gregory
Bird
Bird
Melissa
Du
Du
Nicolas
Pellier
Pellier
Bradley
Pentelute
Pentelute
Stephen
Goldstein
Goldstein
Tristan
Dinsmore
Dinsmore
Hillary
Allen
Allen
Namrata
Turaga
Turaga
Luis
de Lecea
de Lecea
Moaraj
Hasan
Hasan
Further backed by
Wojciech Zaremba
Srinivas Narayanan
Peter Diamandis
Kevin Weil
Julian Schrittwieser
Fidji Simo
Anne Lee Skates
Tyler Cowen
Stephen Malina
Elizabeth Weil
Anne Brandes
Michael Retchin
Rahul Arora
Will DePue
Philip Bogdanov
Justin Mares
Adam Draper
Gus Domel
Brayton Williams
Winnie Qiu
Amol Sarva
Inaki Berenguer
Trevor Chow
Michael Florea
Max Marchione
Larsen Jensen
Riley Loftus
Alexey Guzey
Andrej Karpathy
Context
In the age of ever-improving AI capabilities, we humans are lagging behind.
We're hungry, distractable, and tired.
Roughly half of us will get cancer or heart disease. We fall ill.
A third of our day is spent asleep.
The modern world feeds us slop that leads even further down the drain.
We believe that humans are capable of more.
Nature gave us clues on making this dream real. Research has given us insight into thousands of powerful rare variants.
Program 1/4
Ozempic for Sleep
We spend a third of our lives asleep. Yet, a small subset of humans thrive on four to six hours of sleep per night. They carry short sleeper variants, allowing them to remain healthy while being awake for longer. Previous research reports those short sleepers to have more energy, vigor, and disease resistance. While not definitive evidence, we see them as a proof-of-concept for our biggest frontier for improving human health.
Our first four programs are in sleep. Concretely, we are first working on therapeutics that restore cognitive performance under sleep deprivation, and then towards the end-goal of allowing patients to sleep 1-2 hours less. Our initial focus will be on rare, undertreated sleep diseases like narcolepsy and hypersomnia, while gradually expanding to a broader population, via shift-work sleep disorders.
Our Flagship Therapeutic
The world's most successful drug is a peptide: In 2025, Tirzepatide made $36B.
What's the model that will design the next Tirzepatide?
We’re building a vertically integrated, AI-enabled, deeptech platform to rapidly explore and unlock new human capabilities.
Frontier models won’t be bottlenecked by intelligence. They’ll be bottlenecked by the speed of data and active learning.
The Engines of Creation
SynthesisSPPSStep 1/7
Making peptide and nucleotide therapeutics rapidly with automated polymer synthesis.
